Maravai LifeSciences Announces Refinancing of Credit Agreement, Extending Maturity to 2032
Maravai LifeSciences Holdings, Inc. (
NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, today announced that certain of its subsidiaries have entered into a new credit agreement providing the Company with a $150 million term loan facility and a $30 million revolving credit facility.
Maravai LifeSciences Reports First Quarter 2026 Financial Results
Maravai LifeSciences Holdings, Inc. (Maravai) (
NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, today reported financial results for the first quarter ended March 31, 2026, together with other business updates.
Maravai Lifesciences Reports Fourth Quarter and Full Year 2025 Financial Results
Maravai LifeSciences Holdings, Inc. (Maravai) (
NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, today reported financial results for the fourth quarter and full year ended December 31, 2025, together with other business updates.
Maravai LifeSciences Reports Third Quarter 2025 Financial Results
Maravai LifeSciences Holdings, Inc. (Maravai) (
NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, today reported financial results for the third quarter ended September 30, 2025, together with other business updates.
